ALK-Abello AS (ALK B) - Financial and Strategic SWOT Analysis Review

Date: March 7, 2019
Pages: 50
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: AE31FACB0D2EN
Leaflet:

Download PDF Leaflet

ALK-Abello AS (ALK B) - Financial and Strategic SWOT Analysis Review
ALK-Abello AS (ALK B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

ALK-Abello AS (ALK), a subsidiary of The Lundbeck Foundation discovers, develops and commercializes immunotherapies for allergy prevention and treatment. It markets diagnostics and other services to allergy clinics. The company's allergy immunotherapy product portfolio includes tablet-based vaccines, sublingual or drop-based vaccines, subcutaneous vaccines; and adrenaline auto-injector to treat severe allergic reactions in emergencies (anaphylaxis). ALK’s research and development pipeline products include sublingual immunotherapy tablets for addressing the ragweed, house dust mite and tree pollen allergy. The company’s products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, dog, venom and cat, among others. It has subsidiaries in Europe, North America and Asia-Pacific. ALK is headquartered in Horsholm, Denmark.

ALK-Abello AS Key Recent Developments

Feb 07,2019: ALK releases its annual report 2018
Jan 15,2019: ALK's board of directors to nominate Vincent Warnery as new member of the Board
Jan 11,2019: ALK appoints new head of product supply
Nov 09,2018: ALK Abello: Nine-month interim report 2018
Oct 17,2018: ALK s partner for Japan, Torii, secures pricing for new Japanese cedar SLIT-tablet

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

NOTE: Out of security concerns GlobalData requires using corporate email address.
SECTION 1 - ABOUT THE COMPANY

ALK-Abello AS - Key Facts
ALK-Abello AS - Key Employees
ALK-Abello AS - Key Employee Biographies
ALK-Abello AS - Major Products and Services
ALK-Abello AS - History
ALK-Abello AS - Company Statement
ALK-Abello AS - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
ALK-Abello AS - Business Description
Product Category: Other Products and Services
Overview
Performance
Product Category: SCIT/SLIT-drops
Overview
Performance
Product Category: SLIT Tablets
Overview
Performance
Geographical Segment: Europe
Target Markets
Performance
Geographical Segment: International Markets
Target Markets
Performance
Geographical Segment: North America
Performance
R&D Overview
ALK-Abello AS - Corporate Strategy
ALK-Abello AS - SWOT Analysis
SWOT Analysis - Overview
ALK-Abello AS - Strengths
ALK-Abello AS - Weaknesses
ALK-Abello AS - Opportunities
ALK-Abello AS - Threats
ALK-Abello AS - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
ALK-Abello AS, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 07, 2019: ALK releases its annual report 2018
Jan 15, 2019: ALK's board of directors to nominate Vincent Warnery as new member of the Board
Jan 11, 2019: ALK appoints new head of product supply
Nov 09, 2018: ALK Abello: Nine-month interim report 2018
Oct 17, 2018: ALK s partner for Japan, Torii, secures pricing for new Japanese cedar SLIT-tablet
Oct 17, 2018: New Treatment for House Dust Mite (HDM) Induced Allergic Rhinitis Now Available in US
Sep 17, 2018: Nima partners with global allergy leader ALK for European distribution
Aug 15, 2018: ALK-Abello: Six-month interim report (Q2) 2018
May 04, 2018: ALK Releases Three-month interim report (Q1) 2018
May 04, 2018: ALK Abello: Three-month interim report (Q1) 2018

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

ALK-Abello AS, Key Facts
ALK-Abello AS, Key Employees
ALK-Abello AS, Key Employee Biographies
ALK-Abello AS, Major Products and Services
ALK-Abello AS, History
ALK-Abello AS, Subsidiaries
ALK-Abello AS, Key Competitors
ALK-Abello AS, Ratios based on current share price
ALK-Abello AS, Annual Ratios
ALK-Abello AS, Annual Ratios (Cont.1)
ALK-Abello AS, Annual Ratios (Cont.2)
ALK-Abello AS, Interim Ratios
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
ALK-Abello AS, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

ALK-Abello AS, Performance Chart (2014 - 2018)
ALK-Abello AS, Ratio Charts
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Allergopharma GmbH & Co KG
Allergy Therapeutics Plc
Qualitest Pharmaceuticals
Stallergenes Greer plc
UCB SA
Skip to top


Ask Your Question

ALK-Abello AS (ALK B) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: